Lowest Price Guaranteed
Pages
248
Last Updated
July 2026
View Count
17105
Biomarkers are molecular, cellular, or biochemical changes that can be accurately and repeatably measured and utilized to identify and monitor physiological and pathogenic responses to pharmacological interventions.
The global biomarkers market size is estimated to grow from $62.46 billion in 2024 to $198.58 billion by 2035, at a CAGR of 11.1% during the forecast period, till 2035.
In the recent years, the healthcare industry has observed a paradigm shift in the and development of digital biomarkers that support in are analyzed in silico, using advanced analytical algorithms and artificial intelligence enabled tools. These biomarkers are extensively used to rapidly generate actionable insights and identify previously undetected biological events in the patient.
This segment highlights the distribution of global biomarkers market on the basis of therapeutic area into oncological disorders, cardiovascular disorders, neurological disorders, immunological disorders and other therapeutic areas. Presently, the cancer market segment captures highest share (37%) in the overall market. This is primarily attributed to the growing usage of cancer biomarkers for early detection, prediction and prognosis in the patients.
 |
Based on the type of product, the global biomarkers market is segmented into consumables, services and software. It is worth mentioning that, currently, the consumables market segment accounts for the highest share of the market, attributing to the high consumption of such products (such as reagents and assay kits) for biomarkers-based research and diagnosis. Furthermore, consumables are being widely used in various tests (including DNA / RNA sequencing, immunoassays and proteomics) performed by the researchers during personalized medicine development and cancer research. However, in the future, we believe that services and software is expected to witness a higher CAGR during the forecast period.
The global market for biomarkers is categorized across various types of biomarkers, such as safety biomarkers, efficacy biomarkers and validation biomarkers. Amongst these types, safety biomarkers occupy the highest share (49%) of the market.
This can be attributed to the growing usage of safety biomarkers to measure the efficacy of a new drug (especially personalized therapeutics) that are being developed. However, based on biomarkers market analysis, efficacy biomarkers segment is expected to grow at a higher CAGR during the forecast period.
The global market of biomarkers is segmented across different types of effective biomarkers, such as predictive biomarkers, surrogate biomarkers, pharmacodynamics biomarkers and prognostic biomarkers. Currently, the biomarker market size for predictive biomarkers is expected to be the highest and will likely continue dominating the market during the forecast period.
Based on the application area, the global market is segmented into diagnostics, drug discovery and development, personalized medicine, disease risk assessment, forensic application and other application areas. It is worth highlighting that, currently diagnostics occupies the highest share (38%) of the market.
However, during the forecast period, the drug discovery and development segment is expected to have a high growth rate. This can be attributed to the increasing demand for novel biomarkers for drug discovery, drug identification and prediction of drug response to specific treatment.
Based on the end user, the global market of biomarkers is segmented into hospitals and laboratories, diagnostic centers, research organizations and other end users. It is worth mentioning that hospitals and laboratories segment accounts for the highest biomarkers market share.
The dominance is primarily due to the extensive use of biomarkers for the detection and treatment of cardiovascular diseases, neurological diseases and cancer in hospitals and laboratories. However, in the long run, we believe diagnostic centers are likely to grow at a significant CAGR during the forecast period.
This segment highlights the distribution of global biomarkers market revenue across various geographies, North America, Europe, Asia Pacific, Middle East and North Africa, and Latin America. According to our projection, currently, North America occupies the highest share (45%) of the market.
This is primarily due to the growing burden of chronic diseases in the US, high healthcare expenditure and supportive government initiatives to support the companies for integrating technological advanced biomarker testing. It is worth highlighting that the market in Asia Pacific is expected to grow at a relatively high CAGR, during the forecast period till 2035.
The “Biomarkers Market: Industry Trends and Global Forecasts, Till 2035” market report features an extensive study of the current market landscape, market size and future opportunities within the biomarkers industry, during the given forecast period. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging industry. Key takeaways of the market report have been briefly discussed below.
The biomarkers industry is witnessing substantial growth driven by various factors. These include the increasing global prevalence of cancer and cardiac disorders, as well as advancements in biomarker technology. Technological advancements and innovations in biomarker testing are contributing to market expansion. Other influential factors include regulatory and reimbursement systems, as well as increasing investments in research and development.
Additionally, the increasing focus on personalized medicine is expected to support the growth of the market during the forecast period. Notably, companies that are engaged in the evaluation of new biomarkers are catching the interest of venture capital firms. In August 2024, SphingoTec raised EUR 5 million in Series C funding in order to support the out-licensing of its innovative biomarker Proenkephalin A 119-159 (penKid), (for the assessment of kidney function) and Adrenomedullin 1-52 (bio-ADM) (for the assessment of endothelial function).
Despite the presence of several key drivers, the market has witnessed several challenges that may impede biomarkers market growth during the forecast period. Some of the potential challenges include high complexity associated with development and validation of biomarkers. It is important to highlight here that molecular make-up of advanced biomarkers may vary greatly owing to the structural variation, which further underscores the requirement for specialized technologies for biomarker detection.
Moreover, a number of pharmaceutical companies are collaborating with research organizations to collate evidence on biomarker testing. As such the pharmaceutical companies are also bearing the costs for the biomarker testing for the patients. Therefore, it is imperative to address the associated concerns in order to observe the full potential of the market.
The market presents significant opportunities for growth and innovation, driven by various factors, such as technological advancements, increasing prevalence of chronic diseases, and the growing need for early detection and personalized medicine. The global biomarkers market, including both traditional and digital biomarkers, is expected to experience substantial expansion. The rise of digital biomarkers offers unique insights into patient health by allowing continuous and passive data collection through the use of wearables, sensors and remote technology.
Despite the challenges associated with these biomarkers (such as high product costs and data security concerns), the increasing usage of wearables and ongoing clinical trials in this domain are actively contributing to the surge in demand for digital biomarkers. Overall, the market presents lucrative opportunities for stakeholders, including healthcare companies, hospitals, pharmaceutical companies, and other industry players, to capitalize on the growing demand for biomarker-based diagnostics and personalized medicine.
Currently, the market landscape witnesses the presence of several well-established, small and mid-sized players who are actively engaged in offering consumables, software and services pertaining to the biomarker industry. In order to maintain a competitive edge, these stakeholders are actively taking strategic initiatives, such as forging partnerships, conducting clinical trials and seeking investment opportunities. Overall, the market landscape features several new entrants and large players who are actively exploring technological advancements and making considerable investments to maintain robust presence in this domain.
The global biomarkers market size is valued at $62.46 billion in 2024 and is anticipated to grow at a CAGR of 11.1% during the forecast period till 2035. The market is segmented into different disease indications, with cancer biomarkers expected to hold the largest market share. Key drivers of market growth encompass the focus on early disease detection and management through biomarkers, escalating research and development projects funded by biotechnology and pharmaceutical firms, and the rising incidence of cancer and other diseases. Researchers are actively working on developing biomarkers that allow early detection of cancer.
In August 2024, Illumina announced the United States Food and Drug Administration (USFDA) approval of TruSight™ Oncology (TSO) comprehensive test (a cancer biomarker test) and two companion diagnostic indications. Supporting this GambitBio CEO, Tiffany Ma, mentioned in a recent interview with Cancer Research Horizons “GambitBio exists to push for early detection and reduce the number of cancer-related deaths. We want people to be able to detect what is wrong earlier so clinicians can intervene and treat the problem sooner. Early detection can give people up to 95% survival rate over a 10-year period for certain cancer types.” The company is working on development of an at-home, saliva-based lateral flow test for early cancer detection using proprietary biomarkers.
Many such biomarkers are being developed into liquid biopsy tests. In September 2024, PreAnalytiX, a QIAGEN and BD joint venture launched a liquid biopsy test called PAXgene Urine Liquid Biopsy Set.
Presently, North America holds the highest revenue of the biomarker industry attributed to several factors, including a high disease burden, increased consumer awareness and improvements in healthcare infrastructure. Additionally, the presence of a large population suffering from chronic diseases (including lung cancer and breast cancer), increasing use of biomarkers in personalized medicine, and various growth strategies adopted by key players with established pharmaceutical companies contribute to North America's dominance in the global market. On the other hand, Asia Pacific is expected to register the fastest growth rate in the projected period. This growth is attributed to factors, such as a surge in funding for biomarkers discovery, high prevalence of cancer, rising research initiatives, and low cost of clinical trials in developing nations. Furthermore, an increase in funding for biotechnology and pharmaceutical companies, a rise in the number of CROs, and an increasing application scope of biomarkers are expected to facilitate regional biomarkers market growth during the forecast period.
Examples of the leading players that are engaged in the development of biomarkers are (in alphabetical order) Abbott, Agilent Technologies, Bio Rad Laboratories, Bruker, Charles River Laboratories, CENTOGENE, Enzo Biochem, Epigenomics, Eurofins Scientific, EKF Diagnostics Holdings, Hoffman La Roche, General Electric, LifeSign, Merck, MESO SCALE DIAGNOSTICS, Nexus, PerkinElmer, QIAGEN, Sino Biological and Thermo Fisher Scientific. This market report includes an easily searchable excel database of all the companies worldwide, that are engaged in the development of biomarkers.
The market research report presents an in-depth analysis of the various biomarker companies, across different segments, as defined in the table below:
| Key Report Attributes | Details | |
| Historical Trend | Since 2019 | |
| Forecast Period | Till 2035 | |
| Market Size 2035 | $ 198.58 billion | |
| CAGR (Till 2035) | 11.1% | |
| Type of Offering |
|
|
| Type of Biomarker |
|
|
| Type of Efficacy Biomarker |
|
|
| Application Area |
|
|
| Therapeutic Area |
|
|
| End User |
|
|
| Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
Available | |
One of the key objectives of market report was to estimate the current market size, opportunity and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.
The biomarkers market analysis also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as distribution by type of offering (consumables, services and software), type of biomarker (safety biomarkers, efficacy biomarkers and validation biomarkers), type of efficacy biomarker (predictive biomarkers, surrogate biomarkers, pharmacodynamics biomarkers and prognostic biomarkers), application area (diagnostics, drug discovery and development, personalized medicine, disease risk assessment, forensic application and other application areas), therapeutic area (oncological disorders, cardiovascular disorders, neurological disorders, immunological disorders and other therapeutic areas), end user (hospitals and laboratories, diagnostic centers, research organizations and other end users) and geographical regions (North America, Europe, Asia Pacific, Middle East and North Africa, and Latin America). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this market report are in USD, unless otherwise specified.
Several recent developments have taken place in the biomarkers field, some of which have been outlined below. These developments, even if they took place post the release of our market report, substantiate the overall biomarkers market trends that we have outlined in our analysis.